Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9156343 | 0.87 | CYP1A2 (0.55) | TSHRCYP2D6KDM4EMAPTALDH1A1 | |
| SCHEMBL29935885 | 0.87 | CYP1A2 (0.55) | TSHRCYP2D6KDM4EMAPTALDH1A1 | |
| SCHEMBL2454541 | 0.85 | AKR1B1 (0.46) | TSHRHIF1ACYP2D6AKR1B1CA12 | |
| Hydrochloric Acid SCHEMBL11157053 | 0.85 | CYP1A2 (0.53) | TSHRCYP2D6KDM4EMAPTALDH1A1 | |
| SCHEMBL30695145 | 0.84 | HIF1A (0.55) | TSHRHIF1ACYP2D6AKR1B1CA12 | |
| SCHEMBL15864410 | 0.83 | CA12 (0.72) | TSHRHIF1ACYP2D6CA12CA2 | |
| SCHEMBL5723909 | 0.82 | HPGD (0.67) | TSHRHIF1ACYP2D6AKR1B1MAPT | |
| SCHEMBL30646449 | 0.82 | HPGD (0.67) | TSHRHIF1ACYP2D6AKR1B1MAPT | |
| SCHEMBL23805011 | 0.82 | TSHR (0.57) | TSHRHIF1ACYP2D6AKR1B1CA12 | |
| SCHEMBL4362706 | 0.82 | TSHR (0.57) | TSHRHIF1ACYP2D6AKR1B1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0825294-B1 | Multicomponent system for modifying, decomposing or bleaching lignin, or lignin-containing materials and method of using this system | CONSORTIUM ELEKTROCHEM IND (DE) | 1999-09-15 | — | — | EP | claimed |
| US-10758528-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof | KEMPHARM, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10463660-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof | KEMPHARM, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20170312270-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | ALTER DOMUS (US) LLC | 2017-11-02 | — | — | US | disclosed |
| US-9682076-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof | KEMPHARM, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| CN-101472925-B | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG | 2012-06-13 | — | — | CN | disclosed |
| CN-101472925-A | As adenosine A2APurine derivatives of receptor agonists | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1525247-A2 | COMPLEXING AGENT FOR TREATING METALLIC AND PLASTIC SURFACES | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1461471-A2 | POLYMER DERIVATIVES FOR TREATING METALS | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004001099-A2 | COMPLEXING AGENT FOR TREATING METALLIC AND PLASTIC SURFACES | BASF AKTIENGESELLSCHAFT (DE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003056062-A2 | POLYMER DERIVATIVES FOR TREATING METALS | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-10 | — | — | WO | disclosed |
| EP-0434365-A2 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758528-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof | OPRM1, OPRK1, OPRD1 | TSHR 1155/4885HIF1A 1238/4885CYP2D6 22/4885 |
| US-20170312270-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, OPRD1 | TSHR 1155/4885HIF1A 1238/4885CYP2D6 22/4885 |
| US-10463660-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof | OPRM1, OPRK1, OPRD1 | TSHR 1155/4885HIF1A 1238/4885CYP2D6 22/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TSHR 681/4885HIF1A 2143/4885CYP2D6 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.